Improving Adherence to Statin Therapy Through a Medication Management Application

Launched by UNIVERSITY HOSPITAL, ESSEN · Mar 8, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how a smartphone app called mediteo m+ can help patients stick to their prescribed statin medications, which are used to lower cholesterol and reduce the risk of heart disease. The trial compares the usual care that patients receive for managing their medications with the additional support of this app. Patients who have atherosclerosis—a condition where arteries become narrow due to plaque buildup—and who are just starting high-intensity statin therapy could be eligible to participate. To qualify, participants must be over 18 years old, have elevated cholesterol levels, and have not taken any statin medications in the past 30 days.

Participants in the trial can expect to use the mediteo m+ app, which is designed to help remind them to take their medication and track their adherence. It’s important to note that this study is looking for individuals who can use a smartphone independently, as the app is not provided by the study. People with certain health conditions, such as severe cancer or those who are pregnant, will not be eligible. This trial is currently recruiting participants, and it aims to understand if the app can make a real difference in how well patients follow their medication plans.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age \>18 years
• • Atherosclerosis (neurovascular, cardiac or peripheral) with an indication to start a high intensity statin-therapy (equivalent to 40mg of atorvastatin or 20mg of rosuvastatin; start of statin therapy +/- 10 days of enrolment)
• • Statin naivety
• • LDL-C \>100 mg/dl. No older than 21 days
• Exclusion Criteria:
• • Inability to take medication independently or to use the mediteo m+ app independently (e.g. people in need of care, people with dementia)
• • Patient has no own smartphone (no device provided for this study)
• • Prior drug therapy to lower LDL-C within the last 30 days
• • Active cancer (defined as a diagnosis of cancer within 6 months before enrolment, any treatment for cancer within the previous 6 months, or recurrent or metastatic cancer) or other severe concomitant disease with a life expectancy of \<6 months
• • Use of a digital therapy management application (including mediteo or mediteo m+) within the last month
• • Participation in another interventional trial
• • Pregnancy
• • Inability or unwillingness to provide informed consent